Certara Outlines AI Push, Cost Cuts and New Growth Engines at Jefferies Conference
Key takeaways
- Certara Outlines AI Push, Cost Cuts and New Growth Engines at Jefferies Conference Certara logo Market Beat Mon, June 8, 2026 at 1:02 AM GMT+7 7 min read CERT Key Points Interested in Certara, Inc.?
- Certara is reorganizing around two growth engines — ACE for accelerating clinical evidence and MID3 for model-informed drug development and discovery.
- AI is becoming central to both Certara’s products and internal operations.
Certara Outlines AI Push, Cost Cuts and New Growth Engines at Jefferies Conference Certara logo Market Beat Mon, June 8, 2026 at 1:02 AM GMT+7 7 min read CERT Key Points Interested in Certara, Inc.? Here are five stocks we like better.
Certara is reorganizing around two growth engines — ACE for accelerating clinical evidence and MID3 for model-informed drug development and discovery. Management says the realignment is meant to simplify operations, improve accountability and sharpen go-to-market execution.
AI is becoming central to both Certara’s products and internal operations. The company is embedding AI into existing tools, developing new AI-enabled modules, and using it internally to drive productivity gains across functions like R&D, finance and IT.